Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 5/20 | 0.47 |
| ▸ | MMP13 | P45452 | 5/20 | 0.47 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | MMP8 | P22894 | 3/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | MMP7 | P09237 | 2/20 | 0.47 |
| ▸ | MMP14 | P50281 | 2/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | MMP10 | P09238 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735054 | 0.88 | MMP13 (0.52) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6727302 | 0.88 | MMP13 (0.64) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6727259 | 0.87 | MMP1 (0.43) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6827826 | 0.86 | CYP4F2 (0.43) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6976767 | 0.84 | USP2 (0.45) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6968315 | 0.80 | CYP4F2 (0.45) | MMP1MMP13EPHX2CYP4F2CYP4A11 | |
| SCHEMBL6946607 | 0.80 | SMN1; SMN2 (0.47) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6732559 | 0.78 | MMP13 (0.53) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6731754 | 0.78 | USP2 (0.47) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6730211 | 0.77 | HDAC3 (0.46) | MMP1MMP13MMP9MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6680338-B2 | MATRIX METALLOPROTEINASE AND TUMOR NECROSIS FACTOR INHIBITORS; ANTICARCINOGENIC AGENTS; RHEUMATOID ARTHRITIS | DARWIN DISCOVERY LTD. (GB) | 2004-01-20 | — | — | US | claimed |
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2003-12-25 | — | — | US | claimed |
| EP-1053233-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-08-20 | — | — | EP | claimed |
| EP-1053233-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2000-11-22 | — | — | EP | claimed |
| WO-1999040080-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 1999-08-12 | — | — | WO | claimed |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | MONTANA JOHN GARY (GB) | 2004-07-01 | — | — | US | disclosed |
| US-6680338-B2 | MATRIX METALLOPROTEINASE AND TUMOR NECROSIS FACTOR INHIBITORS; ANTICARCINOGENIC AGENTS; RHEUMATOID ARTHRITIS | DARWIN DISCOVERY LTD. (GB) | 2004-01-20 | — | — | US | disclosed |
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-1053233-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-08-20 | — | — | EP | disclosed |
| EP-1053233-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999040080-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | HCAR1, HCAR2, HCAR3 | MMP1 843/4885MMP13 694/4885MMP9 631/4885 |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, CBR1 | MMP1 770/4885MMP13 986/4885MMP9 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.